Cvkd stock forecast

You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. As at December 2024, Cadrenal Therapeutics had cash of US$10m and no debt. Looking at the last year, the company burnt through US$7.4m. Therefore, from December 2024 it had roughly 16 months of cash runway. While that cash runway isn't too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. You can see how its cash balance has changed over time in the image below. To see Spark’s full report on CVKD stock, click here . Investors evaluating the "cvkd stock forecast" weigh geopolitical supply chain risks, though diversification of suppliers mitigates exposure. This risk management supports consistent quarterly guidance.